Grünenthal announced today that its U.S. subsidiary, Averitas Pharma, Inc., has completed recruitment for the Phase III clinical trial AV001. The trial investigates the efficacy, safety and ...

Averitas Pharma aims to submit a supplemental new drug application (sNDA) in 2026. QUTENZA (capsaicin) 8% topical system is approved in the US for the treatment of neuropathic pain associated with ...

and neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet in adults. - Topline results are expected in Q4 2025 and Averitas Pharma aims to submit a supplemental new drug ...

In the United States, out-of-pocket (OOP) costs of brand-name medications for neurological disorders increased significantly ...

New data will showcase significantly increased and sustained minimal residual disease (MRD) negativity rates, reinforcing the potential of ...

The new findings show that ADCs, just like chemotherapy ... contributing to chemotherapy-induced peripheral neuropathy. ADCs, ...

London - Abu Dhabi – Oxford Cannabinoid Technologies (“OCT” or “the Company”) is pleased to announce the successful ...

Brad Axis Brain and Back Institute +1 (817) 502-7411 ... Visit us on social media: Facebook X LinkedIn YouTube ...